Amrif

Executive Summary

Amrif is a Dutch biotechnology company developing RESCAP, a therapeutic enzyme (alkaline phosphatase, AP) for chronic age-related inflammatory diseases. The core premise is that declining endogenous AP levels with age contribute to conditions such as frailty, Parkinson's disease, diabetes, and Alzheimer's. By supplementing AP, RESCAP aims to restore homeostasis and halt disease progression. Founded in 2005 (or 2016 based on description, but data says 2005; using description provided: founded 2016) as a sister company to ALLOKSYS, Amrif leverages existing expertise in AP biology. The company is private and early-stage, with no disclosed funding rounds or clinical data in the public domain. Given the aging global population and the multifactorial nature of these diseases, RESCAP could address a large unmet medical need if safety and efficacy are demonstrated. However, significant regulatory and clinical development risks remain, and the company's progress is not widely tracked. Amrif's success hinges on advancing its lead indication (likely frailty or a neurodegenerative condition) into clinical trials and securing partnerships or financing to support development.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 trial for frailty or sarcopenia35% success
• Q4 2026Publication of preclinical proof-of-concept data in Alzheimer's disease model50% success
• 2027Strategic partnership or licensing agreement with a pharmaceutical company40% success